Thromboembolic Disorders: Treatments
Anticoagulants, antiplatelets, and thrombolytics for the treatment and/or prophylaxis of venous and arterial thrombosis.
Diagnosis & Disease Information
Anticoagulant Dosing Conversions
Recommended dosing conversions for anticoagulants such as warfarin, heparin, and dabigatran.
Scemblix Approved for Ph+ Chronic Myeloid Leukemia in Chronic Phase
Asciminib inhibits the ABL1 kinase activity of the BCRABL1 fusion protein, by binding to the ABL myristoyl pocket.
FDA Approves Lenalidomide Capsules in 2.5mg, 20mg Strengths
The company also received tentative approval for the 5mg, 10mg, 15mg, and 25mg strengths.
Tazverik Granted Accelerated Approval for Follicular Lymphoma
Tazverik, a methyltransferase inhibitor, is already indicated for the treatment of patients aged ≥16 years with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.
FDA Panel Backs Pexidartinib for Rare Tumor, Votes Against Quizartinib for FLT3-ITD AML
The Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee recently voted on 2 investigational therapies being developed by Daiichi Sankyo: pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT), and quizartinib for the treatment of adults with relapsed/refractory FLT3-ITD acute myeloid leukemia (AML).
- Loading...
Loading...
Next post in Hematologic Cancers
Loading... 
Loading...